KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Non-Current Debt (2016 - 2025)

Thermo Fisher Scientific's Non-Current Debt history spans 17 years, with the latest figure at $35.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 23.37% year-over-year to $35.9 billion, compared with a TTM value of $35.9 billion through Dec 2025, up 23.37%, and an annual FY2025 reading of $35.9 billion, up 23.37% over the prior year.
  • Non-Current Debt for Q4 2025 was $35.9 billion at Thermo Fisher Scientific, up from $31.9 billion in the prior quarter.
  • The five-year high for Non-Current Debt was $35.9 billion in Q4 2025, with the low at $18.6 billion in Q2 2021.
  • Average Non-Current Debt over 5 years is $29.2 billion, with a median of $30.4 billion recorded in 2023.
  • Year-over-year, Non-Current Debt skyrocketed 69.22% in 2021 and then decreased 10.59% in 2022.
  • Tracing TMO's Non-Current Debt over 5 years: stood at $32.3 billion in 2021, then decreased by 10.59% to $28.9 billion in 2022, then grew by 8.3% to $31.3 billion in 2023, then fell by 7.18% to $29.1 billion in 2024, then increased by 23.37% to $35.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Non-Current Debt are $35.9 billion (Q4 2025), $31.9 billion (Q3 2025), and $33.0 billion (Q2 2025).